Translated title of the contribution | A dose-escalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizumab, a humanised anti-interferon-gamma antibody, in patients with moderate-to-severe Crohn's disease. |
---|---|
Original language | Undefined/Unknown |
Pages (from-to) | 1138-1144 |
Number of pages | 7 |
Journal | Gut |
Volume | 55 |
Publication status | Published - 2006 |
A dose-escalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizumab, a humanised anti-interferon-gamma antibody, in patients with moderate-to-severe Crohn's disease.
W. Reinisch, D.W. Hommes, G. van Assche, J.F. Colombel, J.P. Gendre, B. Oldenburg, A. Teml, K. Geboes, H. Ding, L. Zhang, M. Tang, M. Cheng, S.J.H. van Deventer, P. Rutgeerts, T. Pearce
Research output: Contribution to journal › Article › Academic › peer-review